Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560612 · ClinicalTrials.gov registry record · Phase 4
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
A Phase 4 study, sponsored by Durham VA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00560612 is a Phase 4 study that has completed, run by Durham VA Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00560612, a Phase 4 study, has completed, sponsored by Durham VA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is: 1) To document the effectiveness and tolerability of paroxetine for the treatment of subthreshold posttraumatic stress disorder (PTSD) in veterans in the early post-deployment period; and 2) To determine the potential efficacy of paroxetine in preventing the progression of anxiety symptoms to PTSD and other anxiety disorders, and improving overall veteran function.
Interventions
- DRUG Placebo
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00560612
The ClinicalTrials.gov registry entry for NCT00560612 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durham VA Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00560612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00560612 about?
NCT00560612 is a clinical study titled "Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)". The purpose of this study is: 1) To document the effectiveness and tolerability of paroxetine for the treatment of subthreshold posttraumatic stress disorder (PTSD) in veterans in the early post-deployment period; and 2) To determine the potential efficacy of paroxetine in preventing the progression...
What is the current status of trial NCT00560612?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2006-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00560612?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00560612?
This trial is sponsored by Durham VA Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.